GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biotest AG (XTER:BIO) » Definitions » Profitability Rank

Biotest AG (XTER:BIO) Profitability Rank : 4 (As of Mar. 2024)


View and export this data going back to 1987. Start your Free Trial

What is Biotest AG Profitability Rank?

Biotest AG has the Profitability Rank of 4.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Biotest AG's Operating Margin % for the quarter that ended in Mar. 2024 was 24.54%. As of today, Biotest AG's Piotroski F-Score is 6.


Competitive Comparison of Biotest AG's Profitability Rank

For the Biotechnology subindustry, Biotest AG's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biotest AG's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biotest AG's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Biotest AG's Profitability Rank falls into.



Biotest AG Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Biotest AG has the Profitability Rank of 4.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Biotest AG's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=52.8 / 215.2
=24.54 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Biotest AG has an F-score of 6 indicating the company's financial situation is typical for a stable company.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


Biotest AG Profitability Rank Related Terms

Thank you for viewing the detailed overview of Biotest AG's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Biotest AG (XTER:BIO) Business Description

Traded in Other Exchanges
Address
Landsteinerstrasse 5, Dreieich, DEU, 63303
Biotest AG is a supplier of biological medicines. The company produces its products from human blood plasma or manufactured by using biotechnology methods. It is engaged in the area of hematology, clinical immunology, and intensive care medicine. The operating business segments are Therapy, Plasma and Services, and Other segments. It generates maximum revenue from the Therapy segment. Geographically, it derives a majority of revenue from Central Europe and also has a presence in other countries.